EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Genotype-Guided P2Y 12 -Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI

Wout W A van den Broek iD, Jaouad Azzahhafi iD, Qiu Ying F van de Pol iD, Dean R P P Chan Pin Yin iD, Niels M R van der Sangen iD, Shabiga Sivanesan iD, J Peper iD, Ankie M Harmsze iD, Ronald J Walhout iD, Melvyn Tjon Joe Gin iD, Nicoline J Breet, Jorina Langerveld und 5 weitere

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.016084 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Wout W A van den Broek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (W.W.A.v.d.B., J.A., Q.Y.F.v.d.P., D.R.P.P.C.P.Y., J.P., J.M.t.B.), St. Antonius Hospital, Nieuwegein, the Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Clopidogrel, Purinergic P2Y Receptor Antagonists, Cytochrome P-450 CYP2C19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A genotype-guided de-escalation strategy—switching from a potent P2Y 12 inhibitor to clopidogrel—may reduce bleeding risk in patients with acute coronary syndrome. This analysis evaluated the safety and effectiveness of routine genetic testing to guide antiplatelet therapy in clinical practice. METHODS: In this investigator-initiated, prospective, multicenter implementation study, patients received either standard care, with antiplatelet therapy at the physician discretion, or genotype-guided therapy. In the genotype-guided group, physicians were recommended to switch to clopidogrel in noncarriers of CYP2C19 loss-of-function alleles. The coprimary end points were major adverse cardiac events, a composite of cardiovascular death, myocardial infarction, or stroke, and major or nonmajor clinically relevant bleeding, at 1 year of follow-up. Hazard ratios were adjusted for baseline differences between cohorts using multivariable Cox regression. Net adverse cardiac events comprised all-cause death, myocardial infarction, stroke, stent thrombosis, and major bleeding. A Bonferroni-adjusted significance level of α =0.025 was applied. RESULTS: A total of 9907 patients were included in the analysis. Of these, 1208 (12%) were included in the genotype-guided cohort, whereas 8699 (88%) were assigned to the standard care cohort. Major adverse cardiac events occurred in 107 patients (8.9%) in the genotype-guided cohort and 897 patients (10.3%) in the standard care cohort (adjusted hazard ratio, 1.05 [95% CI, 0.85–1.29]; P =0.64). Major or nonmajor clinically relevant bleeding was reported in 146 patients (12.1%) in the genotype-guided cohort compared with 1384 patients (15.9%) in the standard care cohort (adjusted hazard ratio, 0.79 [95% CI, 0.67–0.94]; P =0.01). There was no significant association with net adverse cardiac events (adjusted hazard ratio, 0.91 [95% CI, 0.76–1.09]; P =0.31). CONCLUSIONS: In patients with acute coronary syndrome receiving antiplatelet therapy, implementation of a CYP2C19 genotype-guided de-escalation strategy in clinical practice was associated with a significant reduction of major and nonmajor clinically relevant bleeding compared with standard care at 12 months, without increasing ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03823547.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeClopidogrelPurinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPercutaneous Coronary InterventionPharmacogenomic VariantsReceptors, Purinergic P2Y12Drug SubstitutionPharmacogenomic TestingHumansMaleHemorrhageFemaleTreatment OutcomeRisk FactorsProspective StudiesTime FactorsMiddle AgedAgedRisk AssessmentPhenotypePredictive Value of TestsClinical Decision-Making

Stichwörter der Autor:innen

acute coronary syndromeclopidogrelcytochrome P450 CYP2C19genotypemyocardial infarction

Substanzen

ClopidogrelPurinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsCYP2C19 protein, humanP2RY12 protein, humanReceptors, Purinergic P2Y12

Autor:innen und Institutionen

  • Department of Cardiology (W.W.A.v.d.B., J.A., Q.Y.F.v.d.P., D.R.P.P.C.P.Y., J.P., J.M.t.B.), St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Department of Cardiology, University Medical Center Maastricht, The Netherlands (W.W.A.v.d.B., J.M.t.B.).
  • Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, the Netherlands (N.M.R.v.d.S., S.S., J.P.S.H., W.J.K.).
  • Department of Clinical Pharmacy (A.M.H.), St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Department of Cardiology, Hospital Gelderse Vallei, Ede, the Netherlands (R.J.W.).
  • Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands (M.T.J.G.).

ORCID-Profile: Wout W A van den Broek, Jaouad Azzahhafi, Qiu Ying F van de Pol, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Shabiga Sivanesan, J Peper, Ankie M Harmsze, Ronald J Walhout, Melvyn Tjon Joe Gin, Yolande Appelman, Ron H N van Schaik, José P S Henriques, Jurriën M Ten Berg

Zitieren

APA

van den Broek, W. W. A., Azzahhafi, J., van de Pol, Q. Y. F., Chan Pin Yin, D. R. P. P., van der Sangen, N. M. R., Sivanesan, S., Peper, J., Harmsze, A. M., Walhout, R. J., Tjon Joe Gin, M., Breet, N. J., Langerveld, J., Appelman, Y., van Schaik, R. H. N., Henriques, J. P. S., Kikkert, W. J., & Ten Berg, J. M. (2026). Genotype-Guided P2Y 12 -Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.016084

Vancouver

van den Broek WWA, Azzahhafi J, van de Pol QYF, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, et al. Genotype-Guided P2Y 12 -Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.016084

BibTeX
@article{vandenBroek2026,
  author = {van den Broek, Wout W A and Azzahhafi, Jaouad and van de Pol, Qiu Ying F and Chan Pin Yin, Dean R P P and van der Sangen, Niels M R and Sivanesan, Shabiga and Peper, J and Harmsze, Ankie M and Walhout, Ronald J and Tjon Joe Gin, Melvyn and Breet, Nicoline J and Langerveld, Jorina and Appelman, Yolande and van Schaik, Ron H N and Henriques, José P S and Kikkert, Wouter J and Ten Berg, Jurriën M},
  title = {Genotype-Guided P2Y 12 -Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.016084}
}
Kostenlos starten →